<DOC>
	<DOCNO>NCT02285647</DOCNO>
	<brief_summary>This open-label , randomize , single-dose , single-center , parallel-group bioequivalence study orally- IV-administered rolapitant healthy male female subject .</brief_summary>
	<brief_title>An Open-Label , Randomized , Pivotal , Bioequivalence Study Oral Intravenous Rolapitant</brief_title>
	<detailed_description>To assess bioequivalence single oral dose 200 mg rolapitant single intravenous dose 185 mg rolapitant administer infusion .</detailed_description>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>8- ( ( 1- ( 3,5-bis ( trifluoromethyl ) phenyl ) ethoxy ) methyl ) -8-phenyl-1,7-diazaspiro ( 4,5 ) decan-2-one</mesh_term>
	<criteria>1 . Subjects must healthy male female age 18 55 year ( inclusive ) . 2 . Female subject childbearing potential must negative pregnancy test Screening visit Day 1 . 3 . Female subject childbearing potential must agree use accepted method birth control ( exclude hormonal birth control method ) 72 hour admission clinical unit study completion . 4 . Subjects must BMI 18.5 32.0 kg/m2 ( inclusive ) weight ≥ 50 kg Screening visit . 5 . Subjects must able provide inform consent risk benefit explain . Subjects must capable understanding , able sign write informed consent willing comply protocol requirement . 6 . Subjects must nontobacco user ( define subject smoke used nicotine product last 90 day administration study drug ) negative cotinine test nicotine Screening visit Day 1 . 7 . Subjects must agree discontinue intake alcohol beverage food know interfere CYP metabolic enzyme : grapefruit quininecontaining food beverage ( e.g. , tonic water , bitter lemon ) , orange juice , prune juice , pomelo , cranberry , pomegranate , star fruit , Seville oranges ( marmalade make ) , garlic supplement , St. John 's Wort licorice 72 hour admission clinical unit completion study . 8 . Subjects must general good health determine Investigator , base prestudy medical surgical history , physical examination clinical laboratory test . 9 . Subjects must cardiovascular ( include 12lead ECG ) function Screening visit clinically significant abnormality determine Investigator . 1 . Subjects participate another investigational study within 30 day 5 halflives test drug 's biologic activity , whichever longer , time first study dose . 2 . Subjects history hypersensitivity rolapitant excipients participate previous rolapitant study within 6 month time first study drug dose administration dose ( Day 1 ) . 3 . Subjects history relevant allergy ( include asthma , food drug allergy ) , determine Investigator . 4 . Subjects significant blood loss , donate receive 1 unit ( 450 mL ) blood within 30 day first study dose . 5 . Subjects receive prescription medication overthecounter ( OTC ) medication herbal supplement within 14 day first study dose . By exception , acetaminophen ≤ 1 g/day permit . 6 . Subjects current recent ( within 1 year Screening visit ) history alcohol abuse , illicit drug use , physical dependence addiction alcohol opioid . 7 . Cholecystectomized subject ( since biliary excretion predominant mode excretion rolapitant ) . 8 . Subjects clinical psychiatric condition prior therapy , Investigator 's opinion , would make subject unsuitable study unable comply dose requirement . 9 . Subjects unwilling unable avoid xanthine caffeinecontaining drink ( include many soft drink , energy drink , coffee tea ) food ( chocolate coffee flavor ) 72 hour admission subject discharge Day 39 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>